Prevalence and Characteristics of Deoxycholate and Liposomal Amphotericin B Adverse Reactions in a Third‐Level Care Hospital: A Retrospective Observational Study
Journal of Clinical Pharmacy and Therapeutics · 2026-01 · 2026 (1)
DOI: 10.1155/jcpt/2980716 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 21.06.2026. Verfasst von Thalia Berenice Jacobo Vargas und 6 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
We aimed to establish the prevalence of adverse reactions associated with the use of deoxycholate and/or liposomal amphotericin B and to determine adherence to World Health Organization (WHO) recommendations to minimize the risk of toxicity.
Methods
Clinical data were collected from records of 143 patients over 18 years of age who were under treatment with amphotericin B (deoxycholate and/or liposomal) for at least 5 days from January 2016 to March 2019 at National Institute of Respiratory Diseases “Ismael Cosío Villegas” in Mexico City. We used MeSH terms to name each formulation of amphotericin B, adverse reactions, and diagnoses. Definitions and classification of the adverse reactions were made in accordance with the Common Terminology Criteria for Adverse Events Version 5.0 and other bibliographic references. Preventability assessment was evaluated using the Schumock and Thornton scale. To determine adherence to WHO recommendations, we evaluated intravenous preemptive hydration, electrolyte supplementation, and laboratory test monitoring.
Results
105 patients (73.4%) were exposed to deoxycholate amphotericin B, 25 patients (17.5%) to liposomal amphotericin B, and 13 patients (9.1%) to both amphotericin B types. Hypokalemia was the most common adverse reaction (76.2%), followed by hypomagnesemia (47.6%), acute kidney injury (40.6%), infusion reactions (33.6%), anemia (20.3%), thrombocytopenia (7%), and neutropenia (4.9%). Electrolyte supplementation was the WHO recommendation that was less performed (28%), while preemptive hydration and laboratory test monitoring were well applied (82.5% and 84.6%).
Conclusion
This study highlights the need to adhere to amphotericin B toxicity prevention recommendations as some of the most common adverse reactions are mostly preventable.
Zitieren
APA
Vargas, T. B. J., Portugal, M. D. C. C., Saldaña, R. B., Ganen, O. R., Murrieta, F. J. F., Topete, V. H. A., & Barrientos, R. S. V. (2026). Prevalence and Characteristics of Deoxycholate and Liposomal Amphotericin B Adverse Reactions in a Third‐Level Care Hospital: A Retrospective Observational Study. Journal of Clinical Pharmacy and Therapeutics, 2026(1). https://doi.org/10.1155/jcpt/2980716
Vancouver
Vargas TBJ, Portugal MDCC, Saldaña RB, Ganen OR, Murrieta FJF, Topete VHA, et al. Prevalence and Characteristics of Deoxycholate and Liposomal Amphotericin B Adverse Reactions in a Third‐Level Care Hospital: A Retrospective Observational Study. Journal of Clinical Pharmacy and Therapeutics. 2026;2026(1). doi:10.1155/jcpt/2980716
BibTeX
@article{Vargas2026,
author = {Vargas, Thalia Berenice Jacobo and Portugal, Miriam del Carmen Carrasco and Saldaña, Renata Báez and Ganen, Odalis Rodríguez and Murrieta, Francisco Javier Flores and Topete, Victor Hugo Ahumada and Barrientos, Ricardo Stanley Vega},
title = {Prevalence and Characteristics of Deoxycholate and Liposomal Amphotericin B Adverse Reactions in a Third‐Level Care Hospital: A Retrospective Observational Study},
journal = {Journal of Clinical Pharmacy and Therapeutics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jcpt/2980716}
}
EUVIMED